Creutzfeldt-Jakob Disease: A Decade of Assistential Activity at Centro Hospitalar de Trás-os-Montes e Alto Douro
DOI:
https://doi.org/10.46531/sinapse/AO/210079/2022Keywords:
Creutzfeldt-Jakob Syndrome/ diagnosis, Creutzfeldt-Jakob Syndrome/ epidemiologyAbstract
Introduction: Sporadic Creutzfeldt-Jakob disease (sCJD) is the most frequent of human prion diseases, with an estimated incidence of 1 case per million / habitants per year. Clinical manifestations include multidomain cognitive impairment with pyramidal, extrapyramidal and/or cerebellar signs. It is a rapidly progressive and fatal disease. Our aim was to do a sociodemographic, clinical and progression evaluation of probable CJD cases diagnosed in Centro Hospitalar de Trás-os-Montes de Alto Douro (CHTMAD) since 2010.Methods: Retrospective, descriptive study based on clinical records of all probable CJD cases diagnosed, consecutively included, between January 2010 and July 2020.
Results: We identified 13 cases of probable DCJ (6 women). Median age at beginning of symptoms was 68 years (44-74). The most common form of presentation was cognitive impairment (46.2%), followed by myoclonus (38.5%), ataxia (23.1%), pyramidal signs (23.1%) and extrapyramidal signs (23.1%). In about 3⁄4 of patients there was an initial period of unspecified symptom such as strange behavior, anorexia, insomnia and dizziness. Neurological observation occurred at a median of 30 days after symptoms installation (15-240). Brain magnetic resonance imaging showed cortical hypersignal (T2/T2FLAIR or diffusion-weighted) in 84.6% of patients and basal ganglia hypersignal in 61.5%. Most frequent electroencephalogram anomaly was the presence of periodic discharges/complexes (46.2%). Cerebrospinal fluid analysis was positive for 14.3.3 protein in all cases. Median survival was 3 months (2-13). Autopsy was authorized in only 5 patients, confirming the diagnosis.
Conclusion: Our group of patients illustrate phenotypic variability of CJD and brings attention to the existence of an initial phase of unspecified symptoms, when prompt investigation may allow earlier diagnosis.
Downloads
References
Brown P, Cathala F, Castaigne P, Gajdusek DC. Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol. 1986;20:597-602. doi: 10.1002/ana.410200507.
Sharma S, Mukherjee M, Kedage V, Muttigi MS, Rao A, Rao S. Sporadic Creutzfeldt-Jakob disease--a review. Int J Neurosci. 2009;119:1981-94. doi: 10.1080/00207450903139762.
Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64:1586-91. doi: 10.1212/01. WNL.0000160117.56690.B2.
Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659-68. doi: 10.1093/brain/awp191. Erratum in: Brain. 2012;135:1335.
U.S. Department of Health & Human Services. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DH-CPP)). [accessed oct 2021]Available at: https://www.cdc. gov/ncezid/dhcpp/index.html
Serviço Nacional de Saúde. [consultado Out 2021] Disponível em: http://www.chtmad.min-saude.pt/orgaos-de-gestao/caracterizacao-da-area-de-influencia/
Instituto Nacional de Estatística. Censos 2021. [consultado Out 2021] Disponível em: https://www.ine.pt/scripts/db_ censos_2021.html
Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322ra9. doi: 10.1126/scitranslmed.aad5169.
Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis. 2020;20):e2-e10. doi: 10.1016/S1473-3099(19)30615-2.
Portal de Saúde Pública. Doença de Creutzfeldt-Jacob [consultado Out 2021] Disponível em: http://portal.anmsp. pt/04-PrevencaoDoenca/DTDOmanual/inf.crtz.jacob.htm
[consultado Out 2021] Disponível em: https://comum. rcaap.pt/bitstream/10400.26/22530/1/Doenças%20de%20 Declaração%20Obrigatória%202013-2016%2c%20Volume%20II%20-%20Regiões.pdf
Direção Geral da Saúde. Doenças de Declaração obrigatória: 2010 a 2013. [consultado Out 2021] Disponível em: https://www.dgs.pt/estatisticas-de-saude/estatisticas-de-saude/publicacoes/doencas-de-declaracao-obrigatoria-2010-2013-volume-ii-pdf.aspx
Qi C, Zhang JT, Zhao W, Xing XW, Yu SY. Sporadic Creutzfeldt-Jakob Disease: A Retrospective Analysis of 104 Cases. Eur Neurol. 2020;83:65-72. doi: 10.1159/000507189.
Klug GM, Boyd A, Lewis V, Douglass SL, Argent R, Lee JS, et al; Australian National Creutzfeldt-Jakob Disease Registry. Creutzfeldt-Jakob disease: Australian surveillance update to December 2005. Commun Dis Intell Q Rep. 2006;30:144-7.
Holman RC, Khan AS, Kent J, Strine TW, Schonberger LB. Epidemiology of Creutzfeldt-Jakob disease in the United States, 1979–1990: analysis of national mortality data. Neuroepidemiology. 1995;14:174–81.
Ministério da Saúde. Tempos médios de espera. [consultado Out 2021] Disponível em: http://tempos.min-saude. pt/#/instituicao/145.
Shi Q, Gao C, Zhou W, Zhang BY, Chen JM, et al. Surveillance for Creutzfeldt-Jakob disease in China from 2006 to 2007. BMC Public Health. 2008;18;8:360.
Appleby BS, Appleby KK, Rabins PV. Does the presentation of Creutzfeldt-Jakob disease vary by age or presumed etiology? A meta-analysis of the past 10 years. J Neuropsychiatry Clin Neurosci. 2007;19:428-35. doi: 10.1176/ jnp.2007.19.4.428.
Green AJ. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem Soc Trans. 2002;30:382-6. doi: 10.1042/bst0300382.
Fourier A, Dorey A, Perret-Liaudet A, Quadrio I. Detection of CSF 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease Patients Using a New Automated Capillary Western Assay. Mol Neurobiol. 2018;55:3537-45. doi: 10.1007/ s12035-017-0607-2.
Wieser HG, Schindler K, Zumsteg D. EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol. 2006;117:935-51. doi: 10.1016/j.clinph.2005.12.007.
Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, et al. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus. 2015;39:E2. doi: 10.3171/2015.8.FOCUS15328.
Heinemann U, Krasnianski A, Meissner B, Kallenberg K, Kretzschmar HA, Schulz-Schaeffer W,et al. Brain biopsy in patients with suspected Creutzfeldt-Jakob disease. J Neurosurg. 2008;109:735-41. doi: 10.3171/ JNS/2008/109/10/0735.
Levy SR, Chiappa KH, Burke CJ, Young RR. Early evolution and incidence of electroencephalographic abnormalities in Creutzfeldt-Jakob disease. J Clin Neurophysiol. 1986;3:1-21. doi: 10.1097/00004691-198601000-00001.
Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004;56:702-8. doi: 10.1002/ana.20261.
Zerr I, Schulz-Schaeffer WJ, Giese A, Bodemer M, Schröter A, Henkel Ket al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol. 2000;48:323-9.
Glatzel M, Stoeck K, Seeger H, Lührs T, Aguzzi A. Human prion diseases: molecular and clinical aspects. Arch Neurol. 2005;62:545-52. doi: 10.1001/archneur.62.4.545.
Ukisu R, Kushihashi T, Kitanosono T, Fujisawa H, Takenaka H, Ohgiya Y,et al. Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease. AJR Am J Roentgenol. 2005;184:560-6. doi: 10.2214/ajr.184.2.01840560.
Alvarez FJ, Bisbe J, Bisbe V, Dávalos A. Magnetic resonance imaging findings in pre-clinical Creutzfeldt-Jakob disease. Int J Neurosci. 2005;115:1219-25. doi: 10.1080/00207450590914491.
Caobelli F, Cobelli M, Pizzocaro C, Pavia M, Magnaldi S, Guerra UP. The role of neuroimaging in evaluating patients affected by Creutzfeldt-Jakob disease: a systematic review of the literature. J Neuroimaging. 2015;25:2-13. doi: 10.1111/jon.12098.
Fragoso DC, Gonçalves Filho AL, Pacheco FT, Barros BR, Aguiar Littig I, Nunes RH, et al. Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis. Radiographics. 2017;37:234-57. doi: 10.1148/rg.2017160075.
Mahale RR, Javali M, Mehta A, Sharma S, Acharya P, Srinivasa R. A study of clinical profile, radiological and electroencephalographic characteristics of suspected Creutzfeldt-Jakob disease in a tertiary care centre in South India. J Neurosci Rural Pract. 2015;6:39-50. doi: 10.4103/0976-3147.143189.
Na DL, Suh CK, Choi SH, Moon HS, Seo DW, Kim SE,et al. Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol. 1999;56:951-7. doi: 10.1001/archneur.56.8.951.
Ukisu R, Kushihashi T, Tanaka E, Baba M, Usui N, Fujisawa H, et al. Diffusion-weighted MR imaging of early-stage Creutzfeldt-Jakob disease: typical and atypical manifestations. Radiographics. 2006;26 Suppl 1:S191-204. doi: 10.1148/rg.26si065503..
European Centre for Disease Prevention and Control. European Creutzfeldt-Jakob Disease Surveillance Network (EuroCJD) [consultado Out 2021] Disponível em: https://www. ecdc.europa.eu/en/about-us/who-we-work/disease-and-laboratory-networks/european-creutzfeldt-jakob-disease
Begué C, Martinetto H, Schultz M, Rojas E, Romero C, D’Giano C, et al. Creutzfeldt-Jakob Disease Surveillance in Argentina, 1997–2008. Neuroepidemiology. 2011;37:193-202. doi: 10.1159/000331907
Nagoshi K, Sadakane A, Nakamura Y, Yamada M, Mizusawa H. Duration of prion disease is longer in Japan than in other countries. J Epidemiol. 2011;21:255-62. doi: 10.2188/jea. je20100085.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ana João Marques, Michel Mendes, Andreia Carvalho, Ricardo Almendra, Andreia Matas, Andreia Veiga, Pedro Guimarães, Ana Graça Velon, Maria do Céu Branco, João Paulo Gabriel, Mário Rui Silva
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.